Table 5.

Performance of early-phase, late-phase, dual-phase and Day3–6 models

	Performance
	AUC (95% CI)	Accuracy	Sens.	Spec.	PPV	NPV
Early-phase models (102 primary vs 135 secondary dengue)
Panbio Indirect IgG	0.89 (0.84–0.93)	0.87	0.91	0.82	0.87	0.88
In-house anti-E indirect IgG	0.81 (0.75–0.86)	0.77	0.73	0.82	0.84	0.69
In-house capture IgG	0.83 (0.77–0.89)	0.83	0.81	0.86	0.89	0.77
In-house capture IgM/IgG ratio	0.82 (0.76–0.88)	0.82	0.86	0.76	0.83	0.80
Late-phase models (98 primary vs 116 secondary dengue)
Panbio Indirect IgG	0.89 (0.85–0.93)	0.85	0.93	0.74	0.81	0.90
In-house anti-E indirect IgG	0.73 (0.67–0.80)	0.71	0.82	0.59	0.70	0.73
In-house capture IgG	0.85 (0.80–0.91)	0.85	0.92	0.77	0.82	0.89
In-house capture IgM/IgG ratio	0.90 (0.86–0.94)	0.86	0.94	0.77	0.83	0.91
Dual-phase models (95 primary vs 109 secondary dengue)
Panbio Indirect IgG	0.90 (0.86–0.94)	0.86	0.89	0.83	0.86	0.87
In-house anti-E indirect IgG	0.79 (0.72–0.85)	0.74	0.72	0.77	0.78	0.70
In-house capture IgG	0.86 (0.81–0.92)	0.85	0.91	0.79	0.83	0.88
In-house capture IgM/IgG ratio	0.90 (0.86–0.94)	0.86	0.93	0.79	0.83	0.90
Days 3–6 models (90 primary vs 102 secondary dengue)
Panbio Indirect IgG	0.92 (0.88–0.96)	0.88	0.92	0.82	0.85	0.90
In-house anti-E indirect IgG	0.82 (0.76–0.89)	0.79	0.79	0.79	0.81	0.77
In-house capture IgG	0.89 (0.84–0.94)	0.88	0.91	0.83	0.86	0.89
In-house capture IgM/IgG ratio	0.93 (0.89–0.96)	0.88	0.95	0.79	0.84	0.93